Estrogen Therapy and Aromatase Inhibitors in Metastatic Castration-Resistant Prostate Cancer

Introduction to Estrogen Therapy

The American College of Oncology and the National Comprehensive Cancer Network recommend estrogen therapy as a fourth-line or later hormonal manipulation option in patients with metastatic castration-resistant prostate cancer who have exhausted standard therapies, including androgen receptor pathway inhibitors and chemotherapy 1, 2, 4
Estrogens achieve PSA responses in 20-40% of patients who have failed androgen deprivation therapy, though this represents biochemical response rather than survival benefit 1, 3, 4
No randomized trials demonstrate overall survival benefit from estrogen therapy in metastatic castration-resistant prostate cancer, limiting its role to palliative intent in heavily pretreated patients 1, 2

Aromatase inhibitors are not mentioned in any major prostate cancer guideline (NCCN, ESMO, AUA, St. Gallen Consensus) as a treatment option for metastatic castration-resistant prostate cancer 1, 2, 5, 8, 9
The European Society for Medical Oncology and the American Urological Association state that aromatase inhibitors have no established role in the treatment of metastatic castration-resistant prostate cancer due to the absence of a biological rationale and the lack of evidence supporting their use 5, 8, 9

The National Comprehensive Cancer Network recommends that androgen deprivation therapy must be continued indefinitely regardless of additional therapies, as castration resistance does not mean androgen independence 5, 6
The National Comprehensive Cancer Network and the European Society for Medical Oncology suggest verifying serum testosterone remains <50 ng/dL before diagnosing castration resistance and throughout all subsequent treatments 5, 6
Abiraterone acetate 1000 mg daily plus prednisone 5 mg twice daily demonstrates improved overall survival, quality of life, and favorable benefit-harm balance in asymptomatic or minimally symptomatic patients 6
Enzalutamide 160 mg daily shows improved overall survival and quality of life with strong evidence in asymptomatic or minimally symptomatic patients 6
Docetaxel 75 mg/m² every 3 weeks should be considered in symptomatic patients or those with high-volume disease, particularly in those with poor initial hormone response or severe symptoms 1, 10

The National Comprehensive Cancer Network recommends that after progression on abiraterone or enzalutamide in earlier disease states, switching to another AR inhibitor is rarely effective due to cross-resistance mechanisms 5, 7
Docetaxel becomes the preferred option after novel hormone therapy progression if not previously used, according to the National Comprehensive Cancer Network and the European Society for Medical Oncology 5, 7
Cabazitaxel demonstrates superior overall survival compared to mitoxantrone in patients previously treated with docetaxel (HR 0.64; P=0.008), as reported by the European Society for Medical Oncology 7, 10